ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
- PMID: 20173735
- DOI: 10.1038/nature08825
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C
Abstract
Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.
Comment in
-
Personalized medicine in hepatitis C: from genome-wide association studies to clinical practice.Hepatology. 2010 Jun;51(6):2223-5. doi: 10.1002/hep.23738. Hepatology. 2010. PMID: 20513008 No abstract available.
-
Unraveling the genetic predisposition of ribavirin-induced anaemia.J Hepatol. 2010 Nov;53(5):971-3. doi: 10.1016/j.jhep.2010.06.007. Epub 2010 Jul 21. J Hepatol. 2010. PMID: 20797805 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases